Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
申请人:Boehringer Ingelheim Pharma KG
公开号:US20040058978A1
公开(公告)日:2004-03-25
The present invention relates to new substituted indolinones of general formula
1
wherein
X and R
1
to R
5
are defined as in claim 1, the isomers and the salts thereof which have valuable properties.
The above compounds of general formula I wherein R
1
denotes a hydrogen atom, a C
1-3
-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R
1
does not represent a hydrogen atom, a C
1-3
-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.
NEUE SUBSTITUIERTE INDOLINONE MIT EINER INHIBIERENDEN WIRKUNG AUF VERSCHIEDENE KINASEN UND CYCLIN/CDK-KOMPLEXE
申请人:Boehringer Ingelheim Pharma GmbH & Co.KG
公开号:EP1115704B1
公开(公告)日:2003-06-18
US6855710B2
申请人:——
公开号:US6855710B2
公开(公告)日:2005-02-15
Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs
申请人:Walter Rainer
公开号:US06855710B2
公开(公告)日:2005-02-15
The present invention relates to new substituted indolinones of general formula
wherein
X and R
1
to R
5
are defined as in claim 1, the isomers and the salts thereof which have valuable properties.
The above compounds of general formula I wherein R
1
denotes a hydrogen atom, a C
1-3
-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R
1
does not represent a hydrogen atom, a C
1-3
-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.